glp-1 and gip dual agonist The Emerging Role of Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction Dual GIP/GLP-1 receptor agonists: New

GLP-1RA (such as exendin-4) treatment can reduce the size of MI impacted cardiac volume in rats, inhibit ventricular dilation, myocardial fibrosis and hypertrophy in vivo [72]

Abbreviations GLP-1: Glucagon-like peptide-1 GLP-1RA: Glucagon-like peptide-1 receptor agonist T2DM: Type-2 diabetes mellitus DPP-4: Dipeptidyl peptidase 4 HbA1c: Hemoglobin A1c NASH: Non-alcoholic steatohepatitis NAFLD: Non-alcoholic fatty liver disease Camp: Cyclic adenosine monophosphate PKA: Protein kinase A EPAC: Exchange protein directly activated by cAMP PI3K: Phosphoinositide 3-kinase PYY: Peptide YY CCK: Cholecystokinin GLUT4: Glucose transporter type 4 mTORC1: Mammalian target of rapamycin complex 1 References Ahrn B (2015) Hepato-incretin function of GLP-1: novel concept and target in type 1 diabetes

Semaglutide represents a meaningful advancement in weight loss pharmacotherapy

Raccah D

[DOI] [PMC free article] [PubMed] [Google Scholar] 52.Takase T, Nakamura A, Yamamoto C, et al

GLP-1 effects on energy expenditure A role of endogenous GLP-1R signaling in the control of energy expenditure was inferred from studying mice with congenital GLP-1R deficiency